Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | Chief Strategy Officer | February 14, 2017 | February 16, 2017 |
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Director · Chief Executive Officer | July 14, 2026 | July 16, 2026 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 17, 2026 | June 22, 2026 |
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | CFO & Chief Strategy Officer | December 02, 2019 | December 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date February 14, 2017 · Filed February 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2027-02-13 | Direct | 424,000 |
Reported balance
After 2017-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-14 · Grant · Acquired 424,000 · Balance 424,000 F1: This option vests as to 25% of the shares on January 1, 2018 and as to an additional 6.25% of the original shares each successive three month period through and until January 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests as to 25% of the shares on January 1, 2018 and as to an additional 6.25% of the original shares each successive three month period through and until January 1, 2021.
Cardiff Oncology, Inc.
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,067 |
Reported balance
After 2026-07-14 transaction · row 1
1 source rowRow 1 · 2026-07-14 · Purchase · Acquired 34,364 · Balance 59,067 |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 | Direct | 34,364 |
Reported balance
After 2026-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-14 · Purchase · Acquired 34,364 · Balance 34,364 F1: Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders. F2: The term of exercise is equal to five and one-half years after the Initial Exercise Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders.
F2: The term of exercise is equal to five and one-half years after the Initial Exercise Date.
CytomX Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-16 | Direct | 59,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 59,000 · Balance 59,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Tvardi Therapeutics, Inc.
Report date December 02, 2019 · Filed December 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,441 |
Ending reported balance
After 2019-12-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-12-02 · Grant · Acquired 8,333 · Balance 22,196 F1: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 2, 2019. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Row 2 · 2019-12-04 · Sale · Disposed 4,755 · Balance 17,441 F2: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person. F3: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 2, 2019. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
F2: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person.
F3: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2026 Filed Jul 16, 2026 20:01 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock Purchase Warrant · Derivative | 34,364 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001193125-26-306072 · ownership.xml · derivative · entry 2 Mohindru Mani · CIK 0001664708 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,364 Underlying: Common Stock · 34,364 shares Expires not disclosed F1 · derivative.exercise_date: Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders. F2 · derivative.expiration_date: The term of exercise is equal to five and one-half years after the Initial Exercise Date. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 20:01 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 34,364 | $1.46 | $49,999.62 |
DisclosureSEC source: 0001193125-26-306072 · ownership.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,067 Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 13:00 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 24,703 | $1.21 | $29,890.63 |
DisclosureSEC source: 0001664708-26-000002 · ownership.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,703 Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 59,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001610717-26-000278 · form4.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:16 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 600,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001193125-26-140164 · ownership.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 968,766 Underlying: Common Stock · 600,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: 150,000 vest on March 31, 2027 and 12,500 vest monthly for 36 months thereafter Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:01 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001193125-26-056994 · ownership.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,766 Underlying: Common Stock · 200,000 shares Expires 2036-02-17 Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 13:38 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001641172-25-017070 · ownership.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,766 Underlying: Common Stock · 40,565 shares Expires 2035-06-26 Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001610717-25-000213 · form4.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:09 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 29,700 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001628280-24-030641 · wk-form4_1719864546.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,201 Underlying: Common Stock · 29,700 shares Expires 2034-06-27 Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:34 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001610717-24-000246 · form4.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:03 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 27,700 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-23-022732 · wk-form4_1687294992.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,501 Underlying: Common Stock · 27,700 shares Expires 2033-06-15 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001610717-23-000182 · form4.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:07 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001567619-22-013074 · doc1.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 23:42 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 26,800 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001628280-22-005794 · wf-form4_164695571887372.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,801 Underlying: Common Stock · 26,800 shares Expires 2032-03-09 Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 22:48 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-21-012372 · doc1.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:12 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 44,001 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001628280-21-012175 · wf-form4_162370155455648.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,001 Underlying: Common Stock · 44,001 shares Expires 2031-06-10 F1 · derivative.exercise_date: 14,667 vest on 6/10/2022, 6/10/2023, and 6/20/2024 Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:41 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0001567619-20-021372 · doc1.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-12-15 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from December 16, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 00:50 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 4,755 | $17.05 | $81,072.75 |
DisclosureSEC source: 0001209191-19-059183 · doc4.xml · nonDerivative · entry 2 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,441 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person. F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2). Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:50 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059183 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,196 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 2, 2019. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 21:46 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 37,431 | $0.00 Strike: $14.06 | $0.00 |
DisclosureSEC source: 0001209191-19-042480 · doc4.xml · derivative · entry 3 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,444 Underlying: Common Stock · 37,431 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F3 · derivative.exercise_date: One-fourth (1/4th) of the 385,000 shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 21:46 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 37,431 | $25.00 | $935,775.00 |
DisclosureSEC source: 0001209191-19-042480 · doc4.xml · nonDerivative · entry 2 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,863 F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 - $25.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 21:46 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 37,431 | $14.06 | $526,279.86 |
DisclosureSEC source: 0001209191-19-042480 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. Read SEC document |
| May 29, 2019 Filed May 30, 2019 22:17 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,496 | $21.39 | $53,389.44 |
DisclosureSEC source: 0001209191-19-033517 · doc4.xml · nonDerivative · entry 2 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,863 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person. F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| May 28, 2019 Filed May 30, 2019 22:17 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033517 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,359 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on May 28, 2019. The vested shares represent one-third of the total number of shares subject to the award, and the remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:42 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,041 | $0.00 Strike: $14.06 | $0.00 |
DisclosureSEC source: 0001209191-19-019712 · doc4.xml · derivative · entry 3 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,875 Underlying: Common Stock · 16,041 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F2 · derivative.exercise_date: One-fourth (1/4th) of the 385,000 shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:42 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 16,041 | $19.12 | $306,703.92 |
DisclosureSEC source: 0001209191-19-019712 · doc4.xml · nonDerivative · entry 2 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,026 F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:42 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 16,041 | $14.06 | $225,536.46 |
DisclosureSEC source: 0001209191-19-019712 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0001209191-19-018220 · doc4.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:54 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 4,500 | $12.55 | $56,475.00 |
DisclosureSEC source: 0001209191-19-000403 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,026 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.53 - $12.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:17 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 12,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064403 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,526 F1 · shares: Represents the vesting in full of a performance-based restricted stock unit award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the award, such award was not reportable under Section 16 until vesting was determined, which occurred on December 27, 2018. Each restricted stock unit represented the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,042 | $0.00 Strike: $14.06 | $0.00 |
DisclosureSEC source: 0001209191-18-058944 · doc4.xml · derivative · entry 3 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,916 Underlying: Common Stock · 16,042 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F2 · derivative.exercise_date: One-fourth (1/4th) of the 385,000 shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 16,042 | $18.50 | $296,777.00 |
DisclosureSEC source: 0001209191-18-058944 · doc4.xml · nonDerivative · entry 2 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 16,042 | $14.06 | $225,550.52 |
DisclosureSEC source: 0001209191-18-058944 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 20:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,042 | $0.00 Strike: $14.06 | $0.00 |
DisclosureSEC source: 0001209191-18-055685 · doc4.xml · derivative · entry 3 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,958 Underlying: Common Stock · 16,042 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 20:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 16,042 | $20.19 | $323,887.98 |
DisclosureSEC source: 0001209191-18-055685 · doc4.xml · nonDerivative · entry 2 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.72 - $20.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 20:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 16,042 | $14.06 | $225,550.52 |
DisclosureSEC source: 0001209191-18-055685 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2017 Filed Aug 24, 2017 21:52 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 385,000 | $0.00 Strike: $14.06 | $0.00 |
DisclosureSEC source: 0001209191-17-050188 · doc4.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,000 Underlying: Common Stock · 385,000 shares Expires 2027-08-15 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares shall vest and become exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 21:36 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 424,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001209191-17-011478 · doc4.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,000 Underlying: Common stock · 424,000 shares Expires 2027-02-13 F1 · derivative.exercise_date: This option vests as to 25% of the shares on January 1, 2018 and as to an additional 6.25% of the original shares each successive three month period through and until January 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.